ATOXIGEN is a private CRO specialized in safe pharmacology and in the evaluation of a substance’s efficiency in healthcare, veterinary and environmental.

We provide our customers with predictive and preclinical toxicity biomarkers using new bioassays.

Our services allow new drug manufacturers to have maximum data and facilitate the decision–making process according to Benefit-Risk Assessment.

We bring you customized solutions and know-how which will raise the added-value that you need to achieve your targets.

ATOXIGEN offers a wide range of tests including in vitro and ADME Tox models

• by micromethod testing
• use small quantities of substances
• are compatible with hydrophobic substances and mixed chemicals

Agreement and Quality

CIR – French “Crédit Impôts Recherche” approval
GLP
traceability, confidentiality, standardized operating procedures (OECD, EU, ISO, ASTM).

Integrity: Studies are rigorously performed

Biological tests platforms: ethically compatible with European regulations

Respect of the 3Rs: Refinement, Replacement and Reduction of the tests on animals.

Innovation

We adapt our know-how to your changing needs and to the evolution of regulation.

Private partners: Millegen, Protenia, Chemsteps, Fonderephar

Public partners: University of Bordeaux I, CNRS, IRA, UNITEC, PTIB

Pharmaceutical drugs, cosmetics, food additives.

Biocides, chemical substances, phytopharmaceutical

REACH 1907/2006/CE

Water quality : 2000/60/CE

Founders: Saadia BERRADA (Ph.D), François PELLEGRINI (Ph.D), Hakim KHARRAT (Ph.D) MBA in innovation and Saad BERRADA (Ph.D) and attorney at law .

ATOXIGEN is supported by: OSEO, Regional council of Aquitaine, Innovalis, EADS and won the prize “Réseau d’entreprendre d’Aquitaine”

Mission Statement: Help Pharmaceutical, Nutraceutical, Cosmetic and Chemical companies to optimize their research and secure their drugs and chemicals.

Activity in brief : Provider of preclinical predictive toxicity biomarkers.